Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cybrexa Therapeutics
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Subjects must have histologically- or cytologically-diagnosed epithelial high-grade serous cancer of the ovary, fallopian tube cancer or primary peritoneum cancer that is refractory to prior therapy and must have platinum-resistant disease defined as:
* Subjects who have received only 1 platinum-based chemotherapy regimen for at least 4 cycles of platinum must have disease progression on treatment or occurring ≤ 26 weeks after their last dose of platinum.
* Patients who have progressed following a second course of a platinum based regimen.
* Subjects may have up to 2 additional systemic regimens for advanced or metastatic disease. Maintenance regimens (e.g., with a PARP inhibitor or bevacizumab) are not considered separate regimens.
Age greater than or equal to 18 years at the time of signing the informed consent form (ICF).
Has measurable disease per RECIST 1.1.
Has provided written informed consent.
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Adequate liver, renal, hematologic, pulmonary and coagulation function.
You may not be if
Cytotoxic chemotherapy, biologic agent, investigational agent, or radiation therapy within 3 weeks prior to the first dose of CBX-12.
Subjects who are currently receiving any other anticancer or investigational agent(s).
Clinically significant intercurrent disease.
Active human immunodeficiency virus (HIV) infection.
